The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Taysha Gene Therapies Inc shares valued at $2,999,999 were purchased by Manning Paul B on Jun 27 ’24. At $2.25 per share, Manning Paul B acquired 1,333,333 shares. The insider’s holdings grew to 1,333,333 shares worth approximately $2.59 million following the completion of this transaction.
As published in their initiating research note from BMO Capital Markets on June 27, 2024, Taysha Gene Therapies Inc [TSHA] has been an Outperform and the price target has been revised to $5. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in early April. As of February 01, 2023, Jefferies has decreased its “Buy” rating to a “Hold” for TSHA. Earlier on January 27, 2023, Morgan Stanley downgraded its rating. Their new recommendation was “an Equal-weight” for TSHA stock which previously was a “an Overweight”.
Analyzing TSHA Stock Performance
During the last five days, there has been a surge of approximately 6.59%. Over the course of the year, Taysha Gene Therapies Inc shares have jumped approximately 12.14%. Shares of the company reached a 52-week high of $2.0700 on 01/07/25 and a 52-week low of $1.0500 on 04/09/25. A 50-day SMA is recorded $1.5882, while a 200-day SMA reached $1.9178.
Support And Resistance Levels for Taysha Gene Therapies Inc (TSHA)
According to the 24-hour chart, there is a support level at 1.8200, which, if violated, would cause prices to drop to 1.7000. In the upper region, resistance lies at 2.0200. The next price resistance is at 2.1000. RSI (Relative Strength Index) is 67.25 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.3123, which suggests the price will decrease in the coming days. Percent R is at 4.44%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
